Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia

Avest, Ewoud ter; Abbink, Evertine J.; Graaf, Jacqueline de; Tack, Cees J.; Stalenhoef, Anton F. H.

doi:10.1111/j.1365-2362.2005.01549.x

Cited by 41 publications

(30 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, recent large-scale clinical studies have demonstrated that statins, particularly high dose, may increase, not decrease, the onset of new diabetes (75,76). Simvastatin, atorvastatin, or rosuvastatin does not change plasma levels of adiponectin and insulin sensitivity (59,68,77). Old beta-blockers and diuretics seem to have negative effects on insulin sensitivity (78).…”

Section: Properties Of Adiponectin and Inhibitors Of Adiponectin Exprmentioning

confidence: 98%

Adiponectin and Cardiovascular Disease

Han

Quon

Kim

et al. 2007

Journal of the American College of Cardiology

242

View full text Add to dashboard Cite

Adiponectin is a protein secreted specifically by adipose cells that may couple regulation of insulin sensitivity with energy metabolism and serve to link obesity with insulin resistance. Obesity-related disorders including the metabolic syndrome, diabetes, atherosclerosis, hypertension, and coronary artery disease are associated with decreased plasma levels of adiponectin, insulin resistance, and endothelial dysfunction. Adiponectin has insulin-sensitizing effects as well as antiatherogenic properties. Lifestyle modifications and some drug therapies to treat atherosclerosis, hypertension, and coronary heart disease have important effects to simultaneously increase adiponectin levels, decrease insulin resistance, and improve endothelial dysfunction. In this review, we discuss insights into the relationships between adiponectin levels, insulin resistance, and endothelial dysfunction that are derived from various therapeutic interventions. The effects of lifestyle modifications and cardiovascular drugs on adiponectin levels and insulin resistance suggest plausible mechanisms that may be important for treating atherosclerosis and coronary heart disease.

show abstract

Section: Properties Of Adiponectin and Inhibitors Of Adiponectin Exprmentioning

confidence: 98%

Adiponectin and Cardiovascular Disease

Han

Quon

Kim

et al. 2007

Journal of the American College of Cardiology

242

View full text Add to dashboard Cite

show abstract

“…32 It also decreases ox-LDL autoantibodies titers as well as ox-LDL immune complexes. 33 Rosuvastatin reduces the production of several markers of vascular oxidative stress.…”

Section: Antioxidant Propertiesmentioning

confidence: 99%

An Overview of the Extra-Lipid Effects of Rosuvastatin

Kostapanos

Milionis

Elisaf

2008

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

Statins, in addition to their beneficial lipid modulation effects, exert a variety of several so-called "pleiotropic" actions that may result in clinical benefits. Rosuvastatin, the last agent of the class to be introduced, has proved remarkably potent in reducing low-density lipoprotein cholesterol levels. At present, no large-scale primary or secondary prevention clinical trials document either its long-term safety or its effectiveness in preventing cardiovascular events. A substantial number of experimental and clinical studies have indicate favorable effects of rosuvastatin on endothelial function, oxidized low-density lipoprotein, inflammation, plaque stability, vascular remodeling, hemostasis, cardiac muscle, and components of the nervous system. Available data regarding the effects of rosuvastatin on renal function and urine protein excretion do not seem to raise any safety concerns. Whether the established "pleiotropy" and/or lipid-lowering efficacy of rosuvastatin may translate into reduced morbidity and mortality remains to be shown in ongoing clinical outcome trials.

show abstract

“…While these possible adverse side-effects of HMGR inhibition could explain the greater diabetogenicity of atorvastatin, simvastatin, and rosuvastatin that generally promote, especially at high-doses, an increased risk of T2D development, 53,55,60 these statins have also been shown to improve insulin sensitivity in some populations with diabetes. [61][62][63][64][65][66][67][68][69] Similarly, although the preponderance of studies with pravastatin suggest that this statin reduces T2D risk, a significant relative increase in diabetes incidence has been observed in elderly patients. 70 Two recent meta-analyses of large randomized, controlled trials found that either being older (average age >60 years) or being treated with intensive-dose statin therapy leads to a higher incidence of new-onset diabetes.…”

Section: Review Diabetesmentioning

confidence: 99%

New Aspects of Cellular Cholesterol Regulation on Blood Glucose Control—Review and Perspective on the Impact of Statin Medications on Metabolic Health

Grice

Elmendorf

2017

US Endocrinology

View full text Add to dashboard Cite

Cholesterol is an essential component of cell membranes, and during the past several years, diabetes researchers have found that membrane cholesterol levels in adipocytes, skeletal muscle fibers and pancreatic beta cells influence insulin action and insulin secretion. Consequently, it is thought that dysregulated cell cholesterol homeostasis could represent a determinant of type 2 diabetes (T2D). Recent clinical findings compellingly add to this notion by finding increased T2D susceptibility in individuals with alterations in a variety of cholesterol metabolism genes. While it remains imperfectly understood how statins influence glucose metabolism, the fact that they display an influence on blood glucose levels and diabetes susceptibility seems to intensify the emerging importance of understanding cellular cholesterol in glucose metabolism. Taking this into account, this review first presents cell system and animal model findings that demonstrate the negative impact of cellular cholesterol accumulation or diminution on insulin action and insulin secretion. With this framework, a description of how changes in cholesterol metabolism genes are associated with T2D susceptibility will be presented. In addition, the connection between statins and T2D risk will be reviewed with expanded information on pitavastatin, a newer statin medication that displays actions favoring metabolic health.

show abstract

Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia

Abstract: Despite marked improvements in lipid and lipoprotein values, low-grade inflammation and oxidative stress, a relatively high dose of rosuvastatin did not change insulin sensitivity in subjects with FCH.

Cited by 41 publications

References 41 publications

Adiponectin and Cardiovascular Disease

Adiponectin and Cardiovascular Disease

An Overview of the Extra-Lipid Effects of Rosuvastatin

New Aspects of Cellular Cholesterol Regulation on Blood Glucose Control—Review and Perspective on the Impact of Statin Medications on Metabolic Health

Contact Info

Product

Resources

About